Skip to the main content.

MORE
POWER

FOR Streamlined Bispecifics PRODUCTION

Experience the power of Integrated, End-to-End Bispecific Antibody Production.

 
Introducing our breakthrough platform approach for the efficient production of bispecific molecules in an integrated, streamlined workflow from cell line development through to cGMP manufacturing.
 
High-quality clinical bulk drug substances under accelerated timelines.
That's the power you have with KBI and Selexis.
That's the power of together.
 
selexis-kbi
 

MORE POWER

TO MANUFACTURE YOUR MOST COMPLEX MOLECULES

 

The fully integrated Selexis and KBI development platform encompasses the efficient production of bispecific molecules in a streamlined way, from cell line development (CLD) to cGMP manufacturing. The two companies have developed a seamless approach to optimize the client experience, delivering high quality bulk drug substances under accelerated timelines.

 

Ready to Learn More? 

MORE POWER
TO INTEGRATE, INNOVATE, REDUCE RISK, COLLABORATE

There is a global need for high-quality, effective, off-the-shelf therapies that can be used immediately, while concurrently avoiding supply chain issues and mitigating process complexities. Bispecific antibodies (bsAbs) are constructed to help meet this need due to their ability to bind to two or more different epitopes, thereby allowing them to perform multiple discrete mechanisms of action. 

The KBI-Selexis partnership offers far more beyond the combination of best-in-class CLD with unparalleled expertise and experience in mammalian-based contract development and manufacturing. These highly productive "client-to-industry" collaborations prioritize quality, efficiencies, and time savings in bsAb production across a diverse portfolio of molecule formats to strengthen client programs.

KBI & Selexis: Offering Industry-leading delivery of bispecific programs through increased quality, efficiency, and time savings.

KBI_Pharma_GVA_20220426_3090

MORE POWER

To Get To First In Human, Faster

Experience More Power:
Get in touch with KBI today